{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:48:07Z","timestamp":1790844487071,"version":"4.1.0"},"reference-count":208,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jpba.2013.07.013","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T12:46:53Z","timestamp":1375274813000},"page":"11-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"special_numbering":"C","title":["Forced degradation and impurity profiling: Recent trends in analytical perspectives"],"prefix":"10.1016","volume":"86","author":[{"given":"Deepti","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan Kumar","family":"Basniwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2013.07.013_bib1","first-page":"8","article-title":"Implementation of revised schedule \u2018M\u2019 and SSI","author":"Roy","year":"2003","journal-title":"The Indian Pharmacist"},{"key":"10.1016\/j.jpba.2013.07.013_bib2","series-title":"International Conference on Harmonization","article-title":"Impurities in new drug substances Q3A (R2)","year":"2006"},{"key":"10.1016\/j.jpba.2013.07.013_bib3","series-title":"Good and Gilman's The Pharmaceutical Basics of Therapeutics","first-page":"3","author":"Hardman","year":"1999"},{"key":"10.1016\/j.jpba.2013.07.013_bib4","series-title":"Identification and Determination of Impurities in Drugs","author":"Gorog","year":"2000"},{"key":"10.1016\/j.jpba.2013.07.013_bib5","series-title":"Impurities Evaluation of Pharmaceuticals","author":"Ahuja","year":"1998"},{"key":"10.1016\/j.jpba.2013.07.013_bib6","series-title":"The National Formulary NF 19, 2000","first-page":"1876","year":"1998"},{"key":"10.1016\/j.jpba.2013.07.013_bib7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/009286159703100303","article-title":"Development of stereoisomeric (chiral) drugs: a brief review of scientific and regulatory considerations","volume":"31","author":"Daniels","year":"1997","journal-title":"Drug Information Journal"},{"key":"10.1016\/j.jpba.2013.07.013_bib8","series-title":"Advanced Chromatographic and Electromigration Methods in Biosciences","first-page":"834","article-title":"Monitoring of process impurities in drugs","author":"Husain","year":"1998"},{"key":"10.1016\/j.jpba.2013.07.013_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0731-7085(03)00293-0","article-title":"An overview of the recent trends in development of HPLC methods for determination of impurities in drugs","volume":"33","author":"Nageswara Rao","year":"2003","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.addr.2006.10.006","article-title":"The role of degradant profiling in active pharmaceutical ingredients and drug products","volume":"59","author":"Alsante","year":"2007","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.jpba.2013.07.013_bib11","series-title":"Handbook of Isolation and Characterization of Impurities in Pharmaceuticals","author":"Ahuja","year":"2003"},{"key":"10.1016\/j.jpba.2013.07.013_bib12","series-title":"Analysis of Drug Impurities","author":"Smith","year":"2007"},{"key":"10.1016\/j.jpba.2013.07.013_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trac.2006.05.011","article-title":"The importance and the challenges of impurity profiling in modern pharmaceutical analysis","volume":"25","author":"G\u00f6r\u00f6g","year":"2006","journal-title":"Trends in Analytical Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/157341208786306199","article-title":"Recent advances in the impurity profiling of drugs","volume":"4","author":"Bartos","year":"2008","journal-title":"Current Pharmaceutical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2006.05.012","article-title":"Analytical methodologies for discovering and profiling degradation-related impurities","volume":"25","author":"Baertschi","year":"2006","journal-title":"Trends in Analytical Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpba.2007.01.019","article-title":"On-line H\/D exchange LC\u2013MS strategy for structural elucidation of pharmaceutical impurities","volume":"44","author":"Liu","year":"2007","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.forsciint.2008.09.012","article-title":"Identification of impurities and statistical classification of methamphetamine hydrochloride drugs seized in China","volume":"182","author":"Zhang","year":"2008","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jpba.2013.07.013_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpba.2007.11.029","article-title":"A validated reversed phase HPLC method for the determination of process-related impurities in almotriptan malate API","volume":"46","author":"Kumar","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.chroma.2008.02.114","article-title":"Ultra rapid liquid chromatography as second dimension in a comprehensive two-dimensional method for the screening of pharmaceutical samples in stability and stress studies","volume":"1190","author":"Huidobroa","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jpba.2007.10.037","article-title":"A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)","volume":"46","author":"Gavin","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jpba.2008.05.018","article-title":"Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets","volume":"48","author":"Kadav","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2008.05.030","article-title":"Stress degradation studies on betahistine and development of a validated stability-indicating assay method","volume":"869","author":"Khedr","year":"2008","journal-title":"Journal of Chromatography B"},{"key":"10.1016\/j.jpba.2013.07.013_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jpba.2008.09.021","article-title":"Application of LC\u2013MSn in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance","volume":"48","author":"Li","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpba.2007.11.015","article-title":"Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study","volume":"46","author":"Rao","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ab.2008.02.014","article-title":"Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatographyelectrospray ionization-mass spectrometry: the obestatin case","volume":"376","author":"Spiegeleer","year":"2008","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jpba.2008.01.050","article-title":"Estimation and characterization of budesonide tablets impurities","volume":"47","author":"Ferraboschi","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2008.05.004","article-title":"HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets","volume":"48","author":"Galanopoulou","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jpba.2008.08.011","article-title":"Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride","volume":"48","author":"Bharathia","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2007.12.021","article-title":"Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product","volume":"47","author":"Mohan","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jpba.2008.07.010","article-title":"A validated, stability-indicating HPLC method for the determination of dexamethasone related substances on dexamethasone-coated drug-eluting stents","volume":"48","author":"Chen","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jpba.2008.02.017","article-title":"Validated stability-indicating HPLC method for the determination of dimethyl-4,4\u2032-dimethoxy-5,6,5\u2032,6\u2032-dimethylene dioxybiphenyl-2,2\u2032-dicarboxylate","volume":"47","author":"Hadad","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.chroma.2007.12.015","article-title":"New gradient high-performance liquid chromatography method for determination of donepezil hydrochloride assay and impurities content in oral pharmaceutical formulation","volume":"1189","author":"Kafkal","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.talanta.2008.07.010","article-title":"Simultaneous determination of econazole nitrate, main impurities and preservatives in cream formulation by high performance liquid chromatography","volume":"77","author":"Galdos","year":"2008","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpba.2007.09.014","article-title":"Study of forced degradation behavior of enalapril maleate by LC and LC\u2013MS and development of a validated stability-indicating assay method","volume":"46","author":"Bhardwaj","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2008.05.014","article-title":"Isolation and characterization of degradation impurities in epirubicin hydrochloride injection","volume":"869","author":"Kumar","year":"2008","journal-title":"Journal of Chromatography B"},{"key":"10.1016\/j.jpba.2013.07.013_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-5173(00)00653-0","article-title":"Crystallization of paracetamol from solution in the presence and absence of impurity","volume":"215","author":"Prasad","year":"2001","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jpba.2013.07.013_bib37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpba.2008.06.013","article-title":"Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances","volume":"48","author":"Bao","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chroma.2008.02.097","article-title":"Spectral correlation of high-performance liquid chromatography-diode array detection data from two independent chromatographic runs Peak tracking in pharmaceutical impurity profiling","volume":"1190","author":"Li","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jpba.2008.08.003","article-title":"LC\u2013UV\u2013PDA and LC\u2013MS studies to characterize degradation products of glimepiride","volume":"48","author":"Bansal","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2008.04.018","article-title":"Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients","volume":"360","author":"Shah","year":"2008","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jpba.2013.07.013_bib41","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jpba.2008.09.015","article-title":"Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance","volume":"48","author":"Chitturi","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.forsciint.2008.09.012","article-title":"Identification of impurities and statistical classification of methamphetamine hydrochloride drugs seized in China","volume":"182","author":"Zhang","year":"2008","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jpba.2013.07.013_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jpba.2008.06.011","article-title":"Application of hydrophilic interaction chromatography for simultaneous separation of six impurities of mildronate substance","volume":"48","author":"Hmelnickis","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib44","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jpba.2008.07.007","article-title":"Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium","volume":"48","author":"Saravanan","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0731-7085(03)00204-8","article-title":"First-order UV-derivative spectrophotometry in the analysis of omeprazole and pantoprazole sodium salt and corresponding impurities","volume":"32","author":"Rajic","year":"2003","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.chroma.2007.11.035","article-title":"Determination of relative response factors of impurities in paclitaxel with high performance liquid chromatography equipped with ultraviolet and charged aerosol detectors","volume":"1177","author":"Sun","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.aca.2008.01.027","article-title":"Enantioseparation and impurity determination of the enantiomers of novel phenylethanolamine derivatives by high performance liquid chromatography on amylase stationary phase","volume":"610","author":"Yang","year":"2008","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.jpba.2013.07.013_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.chroma.2008.05.008","article-title":"Determination of pipecuronium bromide and its impurities in pharmaceutical preparation by high-performance liquid chromatography with coulometric electrode array detection","volume":"1201","author":"B\u0142azewicz","year":"2008","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib49","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jpba.2008.09.005","article-title":"Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium","volume":"48","author":"Bianchini","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jpba.2007.09.012","article-title":"Development and validation of UPLC method for determination of primaquine phosphate and its impurities","volume":"46","author":"Dongre","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jpba.2007.12.017","article-title":"HPLC-DAD and MS\/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers","volume":"48","author":"Kovar\u0131kova","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpba.2007.09.009","article-title":"Development of a validated RP-LC\/ESI-MS\u2013MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations","volume":"46","author":"Rao","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib53","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpba.2007.11.004","article-title":"Impurities of tazarotene: isolation and structural characterization","volume":"46","author":"Brenna","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jpba.2009.06.026","article-title":"LC\u2013UV and LC\u2013MS evaluation of stress degradation behaviour of tenatoprazole","volume":"50","author":"Mahadika","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib55","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpba.2009.05.038","article-title":"A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant","volume":"50","author":"Devi","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpba.2009.05.015","article-title":"Development and validation of a stability-indicating HPLC method for simultaneous determination of salicylic acid, betamethasone dipropionate and their related compounds in Diprosalic Lotion\u00ae","volume":"50","author":"Shou","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpba.2009.05.025","article-title":"LC and LC\u2013MS\/MS study of forced decomposition behavior of anastrozole and establishment of validated stability-indicating analytical method for impurities estimation in low dose anastrozole tablets","volume":"50","author":"Reddy","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpba.2009.02.002","article-title":"The stability of biapenem and structural identification of impurities in aqueous solution","volume":"49","author":"Xia","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib59","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jpba.2009.01.013","article-title":"Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC\/IT\/MS, LC\/TOF\/MS and NMR","volume":"49","author":"Dongre","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jpba.2009.05.017","article-title":"Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC\/MS\/MS","volume":"50","author":"Raman","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib61","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpba.2008.11.027","article-title":"Development and validation of HPLC method for the determination of cyclosporin A and its impurities in Neoral\u00ae capsules and its generic versions","volume":"49","author":"Bonifacio","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jpba.2008.11.015","article-title":"Isolation and structural elucidation of two impurities from a diacerein bulk drug","volume":"49","author":"Ashok","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib63","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jpba.2009.01.034","article-title":"Study of forced degradation behavior of eletriptan hydrobromide by LC and LC\u2013MS and development of stability-indicating method","volume":"50","author":"Jocic","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.aca.2009.04.032","article-title":"Identification and quantitation of trace impurities in fatty alcohol ethoxylates using HPLC and MALDI-TOF mass spectrometry","volume":"654","author":"Lee","year":"2009","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.jpba.2013.07.013_bib65","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jpba.2009.06.004","article-title":"Identification of gentamicin impurities by liquid chromatography tandem mass spectrometry","volume":"50","author":"Grahek","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib66","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpba.2008.12.013","article-title":"Analysis of heparin sodium by SAX\/HPLC for contaminants and impurities","volume":"49","author":"Trehy","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib67","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jpba.2009.02.015","article-title":"An innovative approach to the analysis of 3-[4-(2-methylpropyl)phenyl]propanoic acid as an impurity of ibuprofen on a carbon-coated zirconia stationary phase","volume":"49","author":"Kalafut","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpba.2009.03.017","article-title":"LC\u2013NMR and LC\u2013MS identification of an impurity in a novel antifungal drug icofungipen","volume":"50","author":"Novaka","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jpba.2008.10.002","article-title":"Study of forced decomposition behavior of lamivudine using LC, LC\u2013MS\/TOF and MSn","volume":"49","author":"Bedse","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2009.03.021","article-title":"Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(\u2212)-lansoprazole enantiomers and related impurities","volume":"50","author":"Cirilli","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib71","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.talanta.2009.06.004","article-title":"Development and validation of an analytical method for metformin hydrochloride and its related compound (1-cyanoguanidine) in tablet formulations by HPLC-UV","volume":"79","author":"Rimawi","year":"2009","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2009.03.029","article-title":"Optimization of separation and determination of moxifloxacin and its related substances by RP-HPLC","volume":"50","author":"Djurdjevic","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpba.2009.01.010","article-title":"Identification of a process impurity formed during synthesis of a nevirapine analogue HIV NNRT inhibitor using LC\/MS and forced degradation studies","volume":"49","author":"Qiu","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib74","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jpba.2009.03.003","article-title":"Developing and optimizing a validated isocratic reversed-phase high-performance liquid chromatography separation of nimodipine and impurities in tablets using experimental design methodology","volume":"49","author":"Barmpalexis","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.steroids.2008.10.006","article-title":"Doping in sport-2. Quantification of the impurity 19-norandrostenedione in pharmaceutical preparations of norethisterone","volume":"74","author":"Walker","year":"2009","journal-title":"Steroids"},{"key":"10.1016\/j.jpba.2013.07.013_bib76","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jpba.2009.03.004","article-title":"Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS\u2013MS and 2D-NMR spectroscopy","volume":"49","author":"Rao","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.aca.2009.09.022","article-title":"Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs","volume":"654","author":"Bianchini","year":"2009","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.jpba.2013.07.013_bib78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jpba.2008.12.033","article-title":"Profiling and quantification of isoflavone-C-glycosides impurities in puerarin injection by liquid chromatography coupled to ESI-ion trap mass spectrometry","volume":"49","author":"Zhanga","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpba.2008.10.010","article-title":"Identification, isolation and characterization of process-related impurities in rizatriptan benzoate","volume":"49","author":"Raj","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib80","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.chroma.2008.10.059","article-title":"Chemometrical evaluation of ropinirole and its impurity's chromatographic behavior","volume":"1216","author":"Stojanovic","year":"2009","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jpba.2008.12.025","article-title":"HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug","volume":"49","author":"Peng","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpba.2009.04.038","article-title":"Separation of stereoisomers of sertraline and its related enantiomeric impurities on a dimethylated \u03b2-cyclodextrin stationary phase by HPLC","volume":"50","author":"Rao","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib83","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jpba.2009.01.003","article-title":"Identification and structural elucidation of process impurities generated in the end-game synthesis of taranabant (MK-0364) via cyanuric chloride","volume":"49","author":"Chen","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib84","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jpba.2008.10.024","article-title":"Determination of tropicamide and its major impurity in raw material by the HPLC-DAD analysis and identification of this impurity using the off-line HPLC\u2013FT-IR coupling","volume":"49","author":"Stefanowicza","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jpba.2009.05.024","article-title":"Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist","volume":"50","author":"Sampath","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib86","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpba.2009.01.023","article-title":"Identification, characterization and synthesis of impurities of zafirlukast","volume":"49","author":"Goverdhan","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib87","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jpba.2009.06.024","article-title":"Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents","volume":"50","author":"Chen","year":"2009","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib88","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jpba.2010.01.019","article-title":"Isolation and structure characterization of related impurities in 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate (XQ-1H) bulk drug and quantitation by a validated RP-LC","volume":"52","author":"Liu","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpba.2009.12.011","article-title":"A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities","volume":"52","author":"Srinivasu","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib90","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1016\/j.chroma.2010.08.061","article-title":"Impurity profiling of acetylspiramycin by liquid chromatography\u2013ion trap mass spectrometry","volume":"1217","author":"Wanga","year":"2010","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpba.2009.11.026","article-title":"Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution","volume":"52","author":"Kasawar","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib92","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jpba.2009.10.026","article-title":"Development and validation of a stability-indicating HPLC-UV method for the determination of alizapride and its degradation products","volume":"51","author":"Tamaro","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib93","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1080\/00032711003763624","article-title":"Separation, characterization, and quantification of atorvastatin and related impurities by liquid chromatography\u2013electrospray ionization mass spectrometry","volume":"43","author":"Mornar","year":"2010","journal-title":"Analytical Letters"},{"key":"10.1016\/j.jpba.2013.07.013_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jphotochem.2010.08.019","article-title":"Different photodegradation behavior of barnidipine under natural and forced irradiation","volume":"215","author":"Ioele","year":"2010","journal-title":"Journal of Photochemistry and Photobiology A: Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jpba.2010.01.043","article-title":"Analytical control of process impurities in pazopanib hydrochloride by impurity fate mapping","volume":"52","author":"Li","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib96","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jpba.2009.12.027","article-title":"A validated stability-indicating normal phase LC method for clopidogrel bisulfate and its impurities in bulk drug and pharmaceutical dosage form","volume":"52","author":"Rao","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jpba.2009.10.004","article-title":"LC\/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201","volume":"51","author":"Wanga","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib98","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jpba.2009.09.016","article-title":"A validated stability-indicating UPLC method for desloratadine and its impurities in pharmaceutical dosage forms","volume":"51","author":"Rao","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib99","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jpba.2009.10.025","article-title":"Determination of duloxetine hydrochloride in the presence of process and degradation impurities by a validated stability-indicating RP-LC method","volume":"51","author":"Raman","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jpba.2009.12.018","article-title":"Identification of new impurities of enalapril maleate on oxidation in the presence of magnesium monoperoxyphthalate","volume":"52","author":"Toporisic","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib101","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jpba.2009.09.050","article-title":"Characterization of a novel impurity in bulk drug eprosartan by ESI\/MSn and NMR","volume":"51","author":"Sun","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib102","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpba.2010.06.019","article-title":"Structural elucidation of process-related impurities in escitalopram by LC\/ESI-MS and NMR","volume":"53","author":"Raman","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpba.2009.12.021","article-title":"Structural elucidation of a process-related impurity in ezetimibe by LC\/MS\/MS and NMR","volume":"52","author":"Raman","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1556\/AChrom.22.2010.2.1","article-title":"Development and validation of a stability-indicating UHPLC method for assay of felbamate and related substances","volume":"22","author":"Shetty","year":"2010","journal-title":"Acta Chromatographica"},{"key":"10.1016\/j.jpba.2013.07.013_bib105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jpba.2010.04.004","article-title":"Forced degradation of fentanyl: identification and analysis of impurities and degradants","volume":"53","author":"Garg","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib106","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpba.2010.02.006","article-title":"Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities","volume":"53","author":"Skrlin","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib107","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jpba.2010.06.012","article-title":"A multi-technique approach using LC\u2013NMR, LC\u2013MS, semi-preparative HPLC, HR\u2013NMR and HR\u2013MS for the isolation and characterization of low-level unknown impurities in GW876008, a novel corticotrophin-release factor 1 antagonist","volume":"53","author":"Provera","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib108","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.chroma.2009.11.036","article-title":"Control of impurities in l-aspartic acid and l-alanine by high-performance liquid chromatography coupled with a corona charged aerosol detector","volume":"1217","author":"Holzgrabe","year":"2010","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib109","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jpba.2010.02.021","article-title":"Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate","volume":"52","author":"Zanitti","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jpba.2010.05.010","article-title":"Comparison of impurity profiles of orlistat pharmaceutical products using HPLC tandem mass spectrometry","volume":"53","author":"Schneider","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib111","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpba.2009.07.029","article-title":"Liquid chromatographic analysis of oxytocin and its related substances","volume":"51","author":"Ashenafi","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib112","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpba.2010.04.006","article-title":"Degradation studies of pentoxifylline: isolation and characterization of a novel gem-dihydroperoxide derivative as major oxidative degradation product","volume":"53","author":"Mone","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/chromsci\/48.7.589","article-title":"Simultaneous determination of piracetam and its four impurities by RP-HPLC with UV detection","volume":"48","author":"Araynel","year":"2010","journal-title":"Journal of Chromatographic Science"},{"key":"10.1016\/j.jpba.2013.07.013_bib114","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jpba.2010.04.008","article-title":"Liquid chromatographic separation of pregabalin and its possible impurities with fluorescence detection after postcolumn derivatization with O-phtaldialdehyde","volume":"53","author":"Dousa","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib115","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpba.2010.01.034","article-title":"Identification, isolation and characterization of new impurity in rabeprazole sodium","volume":"52","author":"Rao","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jpba.2009.08.007","article-title":"LCMS using a hybrid quadrupole time of flight mass spectrometer for impurity identification during process chemical development of a novel integrase inhibitor","volume":"51","author":"Novaka","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib117","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jpba.2010.04.003","article-title":"Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor","volume":"53","author":"Chow","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib118","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jpba.2009.10.012","article-title":"Structural elucidation of the rifaximin Ph. Eur. impurity H","volume":"51","author":"Stradia","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib119","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpba.2010.06.004","article-title":"LC\u2013MS\/MS studies of ritonavir and its forced degradation products","volume":"53","author":"Rao","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib120","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpba.2010.01.036","article-title":"Development and validation of a HPLC method for the determination of sertraline and three non-chiral related impurities","volume":"53","author":"Ferrarini","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib121","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jpba.2010.05.022","article-title":"Stability-indicating UPLC method for determination of valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms","volume":"53","author":"Krishnaiah","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib122","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jpba.2010.04.027","article-title":"Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonist","volume":"53","author":"Provera","year":"2010","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib123","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jpba.2010.08.021","article-title":"Separation and characterization of forced degradation products of abacavir sulphate by LC\u2013MS\/MS","volume":"54","author":"Rao","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib124","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jpba.2011.01.035","article-title":"Isolation and identification of five impurities of ALB 109564(a) drug substance","volume":"55","author":"Milanowskia","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jpba.2011.08.022","article-title":"Determination and characterization of degradation products of anastrozole by LC\u2013MS\/MS and NMR spectroscopy","volume":"56","author":"Sitaram","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib126","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1016\/j.chroma.2011.07.069","article-title":"Identification of impurities in artemisinin, their behavior in high performance liquid chromatography and implications for the quality of derived anti-malarial drugs","volume":"1218","author":"Stringham","year":"2011","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib127","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpba.2011.01.002","article-title":"Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate","volume":"55","author":"Chitturi","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jpba.2011.05.011","article-title":"Identification, synthesis and quantification of process-related impurities in auraptene","volume":"56","author":"Li","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jpba.2011.06.025","article-title":"Boron phenylalanine and related impurities: HPLC analysis, stability profile and degradation pathways","volume":"56","author":"Dick","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpba.2011.05.024","article-title":"Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC\/ESI-ITMS and NMR","volume":"56","author":"Raman","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib131","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jpba.2011.05.030","article-title":"Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography\u2013tandem mass spectrometry and semi-preparative chromatographic isolation","volume":"56","author":"Thomas","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib132","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jpba.2010.08.010","article-title":"Detection, identification and quantification of a new de-fluorinated impurity in casopitant mesylate drug substance during late phase development: an analytical challenge involving a multidisciplinary approach","volume":"54","author":"Turcoa","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.talanta.2011.10.001","article-title":"Forced degradation study to develop and validate stability-indicating RP-LC method for the determination of ciclesonide in bulk drug and metered dose inhalers","volume":"87","author":"Elkady","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib134","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.talanta.2010.11.044","article-title":"Identification of impurities in polymyxin B and colistin bulk sample using liquid chromatography coupled to mass spectrometry","volume":"83","author":"Bossche","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib135","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jpba.2010.10.019","article-title":"Development of characterization methods for entacapone in a pharmaceutical bulk","volume":"54","author":"Soukhova","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib136","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jpba.2011.03.005","article-title":"Isolation and structure characterization of related impurities in etimicin sulfate by LC\/ESI-MSn and NMR","volume":"55","author":"Wang","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib137","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molstruc.2011.02.020","article-title":"Physicochemical characterization of ezetimibe and its impurities","volume":"991","author":"Filip","year":"2011","journal-title":"Journal of Molecular Structure"},{"key":"10.1016\/j.jpba.2013.07.013_bib138","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jpba.2011.07.039","article-title":"Study of impurity carryover and impurity profile in febuxostat drug substance by LC\u2013MS\/MS technique","volume":"56","author":"Kadivar","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib139","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.talanta.2011.03.018","article-title":"Fesoterodine stress degradation behavior by liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry","volume":"84","author":"Sangoi","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpba.2011.06.017","article-title":"Qualitative and quantitative studies on impurities in G004, a potential hypoglycaemic agent, using liquid chromatography, nuclear magnetic resonance and mass spectrometry","volume":"56","author":"Liua","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib141","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jpba.2011.07.031","article-title":"Development and validation of liquid chromatography tandem mass spectrometry methods for the determination of gentamicin, lincomycin, and spectinomycin in the presence of their impurities in pharmaceutical formulations","volume":"56","author":"Prcetic","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib142","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1016\/j.chroma.2011.08.025","article-title":"Determination of organic acid impurities in lactic acid obtained by fermentation of sugarcane juice","volume":"1218","author":"Qureshi","year":"2011","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib143","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jpba.2011.03.036","article-title":"Isolation and characterization of process-related impurities and degradation products in larotaxel","volume":"55","author":"Che","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib144","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jpba.2011.06.012","article-title":"Stress degradation studies on lornoxicam using LC, LC\u2013MS\/TOF and LC\u2013MSn","volume":"56","author":"Modhave","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib145","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jpba.2011.07.010","article-title":"Simultaneous determination of Maillard reaction impurities in memantine tablets using HPLC with charged aerosol detector","volume":"56","author":"Rystov","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib146","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jpba.2010.07.018","article-title":"Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance","volume":"54","author":"Karthikeyan","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib147","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.chroma.2011.02.027","article-title":"Development of an orthogonal method for mometasone furoate impurity analysis using supercritical fluid chromatography","volume":"1218","author":"Wang","year":"2011","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib148","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jpba.2011.06.003","article-title":"Characterization and relative response factor determination of process related impurity in naproxen by nuclear magnetic resonance spectroscopy","volume":"56","author":"Iqbal","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib149","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpba.2011.05.003","article-title":"Identification of oxidative degradation impurities of olanzapine drug substance as well as drug product","volume":"56","author":"Rao","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib150","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jpba.2010.10.013","article-title":"Development of a stability-indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms","volume":"54","author":"Krishnaiah","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijms.2011.01.004","article-title":"Structural elucidation of degradation products of olaquindox under stressed conditions by accurate mass measurements using electrospray ionization hybrid ion trap\/time-of-flight mass spectrometry","volume":"303","author":"Liu","year":"2011","journal-title":"International Journal of Mass Spectrometry"},{"key":"10.1016\/j.jpba.2013.07.013_bib152","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jpba.2011.05.037","article-title":"Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase","volume":"56","author":"Murthy","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.microc.2011.06.022","article-title":"Desirability-based optimization and its sensitivity analysis for the perindopril and its impurities analysis in a microemulsion LC system","volume":"99","author":"Malenovi\u0107","year":"2011","journal-title":"Microchemical Journal"},{"key":"10.1016\/j.jpba.2013.07.013_bib154","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijms.2010.06.001","article-title":"Detecting low-level synthesis impurities in modified phosphorothioate oligonucleotides using liquid chromatography\u2013high resolution mass spectrometry","volume":"304","author":"Nikcevica","year":"2011","journal-title":"International Journal of Mass Spectrometry"},{"key":"10.1016\/j.jpba.2013.07.013_bib155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jpba.2011.05.027","article-title":"Identification and control of impurities in streptomycin sulfate by high-performance liquid chromatography coupled with mass detection and corona charged-aerosol detection","volume":"56","author":"Holzgrabe","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib156","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jpba.2010.10.022","article-title":"Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities","volume":"54","author":"Krier","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib157","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jpba.2010.10.001","article-title":"A validated RP-HPLC method for quantitative determination of related impurities of ursodeoxycholic acid (API) by refractive index detection","volume":"54","author":"Peepliwal","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib158","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpba.2011.04.017","article-title":"Characterization of two new potential impurities of valsartan obtained under photodegradation stress condition","volume":"56","author":"Bianchini","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2011.06.002","article-title":"Synthesis and characterization of critical process related impurities of an asthma drug-zafirlukast","author":"Goverdhan","year":"2011","journal-title":"Journal of Saudi Chemical Society"},{"key":"10.1016\/j.jpba.2013.07.013_bib160","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jpba.2011.10.017","article-title":"Forced degradation studies of rapamycin: identification of autoxidation products","volume":"59","author":"Oylera","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib161","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.forsciint.2011.09.026","article-title":"Identification of common impurities present in the synthetic routes leading to 4-methylthioamphetamine (4-MTA). Part II: reductive amination and nitropropene route","volume":"217","author":"B\u0142achut","year":"2012","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jpba.2013.07.013_bib162","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.chroma.2012.03.092","article-title":"Removal of potentially genotoxic acetamide and arylsulfonate impurities from crude drugs by molecular imprinting","volume":"1240","author":"Sz\u00e9kely","year":"2012","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib163","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpba.2012.06.015","article-title":"The impact of impurities in various crude A. annua extracts on the analysis of artemisinin by liquid chromatographic methods","volume":"70","author":"Pilkingtona","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib164","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.saa.2012.06.037","article-title":"Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method","volume":"97","author":"Gupta","year":"2012","journal-title":"Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"},{"key":"10.1016\/j.jpba.2013.07.013_bib165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jpba.2011.12.001","article-title":"Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions","volume":"61","author":"Ueyama","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib166","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejps.2011.12.009","article-title":"Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electrospray orbitrap mass spectrometry \u2013 study of degradation kinetic","volume":"45","author":"Lecoeur","year":"2012","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jpba.2013.07.013_bib167","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bfopcu.2012.02.001","article-title":"Stability indicating HPLC and spectrophotometric methods for the determination of bupropion hydrochloride in the presence of its alkaline degradates and related impurity","volume":"50","author":"Abbas","year":"2012","journal-title":"Bulletin of Faculty of Pharmacy,Cairo University"},{"key":"10.1016\/j.jpba.2013.07.013_bib168","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.talanta.2012.06.015","article-title":"Application of a column classification method in a selectivity study involving caffeine and its related impurities","volume":"99","author":"Szulfer","year":"2012","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2013.07.013_bib169","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jpha.2012.06.003","article-title":"Development and validation of the stability-indicating LC\u2013UV method for the determination of cefditoren pivoxil","volume":"2","author":"Annapurnan","year":"2012","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpba.2011.11.021","article-title":"Identification and characterization of three impurities in clocortolone pivalate","volume":"62","author":"Xu","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib171","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpba.2011.12.014","article-title":"Development of chromatographic methods for the determination of genotoxic impurities in cloperastine fendizoate","volume":"61","author":"Garc\u00eda","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib172","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2012.01.024","article-title":"Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC\u2013ESI-QT\/MS\/MS","volume":"63","author":"Thomas","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib173","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jpha.2012.02.009","article-title":"LC\u2013UV and LC\u2013MS evaluation of stress degradation behavior of desvenlafaxine","volume":"2","author":"Pawar","year":"2012","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib174","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpha.2012.01.003","article-title":"Validated gradient stability indicating HPLC method for determining diltiazem hydrochloride and related substances in bulk drug and novel tablet formulation","volume":"2","author":"Chatpalliwara","year":"2012","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpba.2011.11.028","article-title":"Isolation and characterisation of degradant impurities in dipyridamole formulation","volume":"61","author":"Subbaiah","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib176","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jpba.2011.11.024","volume":"61","author":"Thomas","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib177","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2011.08.025","article-title":"A validated stability indicating ultra performance liquid chromatographic method for determination of impurities in esomeprazole magnesium gastro resistant tablets","volume":"57","author":"Nalwade","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib178","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jpba.2012.06.041","article-title":"Impurity profiling of etimicin sulfate by liquid chromatography ion-trap mass spectrometry","volume":"70","author":"Yuan","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib179","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpba.2011.09.009","article-title":"A stability indicating simultaneous dual wavelength UV\u2013HPLC method for the determination of potential impurities in fampridine active pharmaceutical ingredient","volume":"58","author":"Thomas","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jpba.2012.07.006","article-title":"Design of experiments as a tool for LC\u2013MS\/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids","volume":"70","author":"Szekely","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib181","article-title":"Development and validation of a stability-indicating LC method for simultaneous determination of related compounds of guaifenesin, terbutaline sulfate and ambroxol HCl in cough syrup formulation","author":"Rao","year":"2012","journal-title":"Journal of Saudi Chemical Society"},{"key":"10.1016\/j.jpba.2013.07.013_bib182","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2012.03.022","article-title":"Stability-indicating UPLC method for determination of imatinib mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms","volume":"66","author":"Nageswari","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib183","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chroma.2012.01.020","article-title":"Quantitative high-perforamance liquid chromatography-tandem mass spectrometry impurity profiling methods for the analysis of parentral infusion solutions for amino acid supplementation containing l-alanyl-l-glutamine","volume":"12","author":"Schiesel","year":"2012","journal-title":"Journal of Chromatography A"},{"issue":"4","key":"10.1016\/j.jpba.2013.07.013_bib184","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jpha.2012.03.006","article-title":"A validated stability-indicating LC method for the separation of enantiomer and potential impurities of linezolid using polar organic mode","volume":"2","author":"Rajua","year":"2012","journal-title":"Journal of Pharmaceutical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2012.03.019","article-title":"Application of experimental design for the optimization of forced degradation and development of a validated stability-indicating LC method for luliconazole in bulk and cream formulation","author":"Sonawane","year":"2012","journal-title":"Arabian Journal of Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib186","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.forsciint.2011.01.042","article-title":"Cross-examination of liquid\u2013liquid extraction (LLE) and solid-phase microextraction (SPME) methods for impurity profiling of methamphetamine","volume":"215","author":"Lee","year":"2012","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jpba.2013.07.013_bib187","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpba.2011.09.029","article-title":"Development and validation of reversed phase high performance liquid chromatographic method for determination of moxonidine in the presence of its impurities","volume":"59","author":"Milovanovic","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/AChrom.24.2012.4.5","article-title":"Development and application of stability-indicating HPLC method for the determination of nevirapine and its impurity in combination drug product","volume":"24","author":"Navaneethan","year":"2012","journal-title":"Acta Chromatographica"},{"key":"10.1016\/j.jpba.2013.07.013_bib189","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpba.2011.10.033","article-title":"Quantification of potential impurities by a stability indicating UV-HPLC method in niacinamide active pharmaceutical ingredient","volume":"60","author":"Thomas","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpba.2012.03.031","article-title":"Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloro-phenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist","volume":"66","author":"Gao","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib191","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jpba.2012.05.031","article-title":"Method development and validation study for quantitative determination of 2-chloromethyl-3,4-dimethoxy pyridine hydrochloride a genotoxic impurity in pantoprazole active pharmaceutical ingredient (API) by LC\/MS\/MS","volume":"70","author":"Venugopal","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib192","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2012.03.003","article-title":"A high pH based reversed-phase high performance liquid chromatographic method for the analysis of aminoglycoside plazomicin and its impurities","volume":"66","author":"Tana","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2012.07.005","article-title":"A rapid stability indicating LC-method for determination of praziquantel in presence of its pharmacopoeial impurities","author":"Hashem","year":"2012","journal-title":"Arabian Journal of Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib194","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2011.08.014","article-title":"Identification, characterization and quantification of new impurities by LC\u2013ESI\/MS\/MS and LC\u2013UV methods in rivastigmine tartrate active pharmaceutical ingredient","volume":"57","author":"Thomas","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib195","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jsps.2011.11.006","article-title":"Box-Behnken supported validation of stability-indicating high performance thin-layer chromatography (HPTLC) method: an application in degradation kinetic profiling of ropinirole","volume":"21","author":"Mustafa","year":"2012","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.jpba.2013.07.013_bib196","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpba.2012.07.021","article-title":"Development of a stability-indicating LC method for determination of a synthetic chalcone derivative in a nanoemulsion dosage form and identification of the main photodegradation product by LC\u2013MS","volume":"70","author":"Mattos","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib197","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jpba.2012.04.029","article-title":"Isolation and structure characterization of related impurities in sodium tanshinone IIA sulfonate by LC\/ESI-MSn and NMR","volume":"67\u201368","author":"Wang","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2012.03.022","article-title":"Detection, isolation and characterization of principle synthetic route indicative impurity in telmisartan","author":"Srinivasan","year":"2012","journal-title":"Arabian Journal of Chemistry"},{"key":"10.1016\/j.jpba.2013.07.013_bib199","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpba.2011.12.008","article-title":"Forced degradation study of thiocolchicoside: characterization of its degradation products","volume":"61","author":"Erika","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2012.08.048","article-title":"Impurity profiling of trandolapril under stress testing: structure elucidation of by-products and development of degradation pathway","volume":"438","author":"Dendenia","year":"2012","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.jpba.2013.07.013_bib201","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpba.2012.07.030","article-title":"A novel process related impurity and forced degradation study of synthetic wogonin: development of a liquid chromatographic method for purity control","volume":"71","author":"Xia","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2011.08.043","article-title":"Identification, preparation and UHPLC determination of process-related impurity in zolmitriptan","volume":"58","author":"Dousa","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3797\/scipharm.1109-02","article-title":"Synthesis and characterization of organic impurities in bortezomib anhydride produced by a convergent technology","volume":"80","author":"Ivanov","year":"2012","journal-title":"Scientia Pharmaceutica"},{"key":"10.1016\/j.jpba.2013.07.013_bib204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.aca.2009.09.050","article-title":"Recognizing paracetamol formulations with the same synthesis pathway based on their trace-enriched chromatographic impurity profiles","volume":"655","author":"Dumarey","year":"2009","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.jpba.2013.07.013_bib205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.chroma.2012.03.080","article-title":"Selective extraction of genotoxic impurities and structurally alerting compounds using polymeric ionic liquid sorbent coatings in solid-phase microextraction: Alkyl halides and aromatics","volume":"1240","author":"Ho","year":"2012","journal-title":"Journal of Chromatography A"},{"key":"10.1016\/j.jpba.2013.07.013_bib206","first-page":"532","article-title":"Supercritical fluid extraction: a new milestone in extraction technology","volume":"67","author":"Basniwal","year":"2005","journal-title":"Indian Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.jpba.2013.07.013_bib207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpba.2012.05.025","article-title":"Evaluation of mobile phase gradient supercritical fluid chromatography for impurity profiling of pharmaceutical compounds","volume":"70","author":"Alexander","year":"2012","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.jpba.2013.07.013_bib208","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1573412911208020135","article-title":"Simvastatin: review of updates on recent trends in pharmacokinetics, pharmacodynamics, drug\u2013drug interaction, impurities and analytical methods","volume":"8","author":"Basniwal","year":"2012","journal-title":"Current Pharmaceutical Analysis"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708513003099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708513003099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T23:42:49Z","timestamp":1563579769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708513003099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":208,"alternative-id":["S0731708513003099"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2013.07.013","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forced degradation and impurity profiling: Recent trends in analytical perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2013.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}